Please login to the form below

Not currently logged in
Email:
Password:

GSK to research traditional Chinese medicines

Will investigate how to apply their principles in the quest for new drugs 

GlaxoSmithKline (GSK) is to investigate how to apply the principles of traditional Chinese medicines to its quest to discover new drugs.

To do this the pharma company will create a new Discovery Performance Unit (DPU), to be based in China.

“Within our discovery organisation in China we have created a DPU that will marry traditional Chinese medicine with modern drug discovery and clinical efficacy,” Moncef Slaoui, GSK's chairman of research and development told the Sunday Telegraph.

“With modern technology we have the potential to yield new molecular entities with significant efficacy.”

The announcement follows the completion of a review of the company's DPUs that will see the creation of a total of four new units, with three to close.

The review, which was carried out by a board of senior GSK R&D leaders and people from the venture capital and biotech/pharma investment sectors, was “driven by assessments of potential returns on investment, scientific quality and opportunity”, GSK said.

Its recommendations also include putting more money into six existing DPUs and cutting back on the investment for five units.

The DPU model was established in 2008 to increase the efficiency of GSK's research and development spending and, as of last year, there were 38 units.

These are made up of 5-70 scientists and each DPU focuses on one particular disease or pathway.

Commenting on their progress in his review 2011, CEO Andrew Wittty said: “Over the last three years, I have visited many of the DPUs and am very pleased with the energy, approach and productivity we are seeing from our scientists in these units.”

As a results of the change GSK expects to move up to 30 new drugs into late-stage development in the next three years.

13th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics